GGrantIndex
← Search

CORE--BIOLOGICAL PRODUCTION RESOURCE

$0P30FY2001CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

The purpose of the Biologics Production Shared Resource is four-fold: (1) to develop and optimize production of biologic agents in the most cost- effective manner possible; (2) to optimize methods of purification of biologic agents at high yield; (3) to develop, evaluate and maintain quality control standards for biologic agents intended for intravenous administration in humans and (4) to provide investigators with monoclonal antibodies in large quantities in a form suitable for intravenous administration in humans when necessary. The resource was established in 1992 and fulfills an essential role for peer-reviewed research at the FHCRC. Research activities focus on two areas: (a) production of purified antibodies in amounts ranging from milligrams to grams; and (b) hybridoma development including initial screen of post immunization serum, fusion, post fusion screens, positive well expansion and subcloning of hybridomas. The latter service was established in late 1995 with service support initiated in 1996, to more fully address the needs of FHCRC investigators and to facilitate the development of highly productive cell lines for future production activities.

View original record on NIH RePORTER →